A Study of BBI503 in Adult Patients With Advanced Hepatobiliary Cancer
Status:
Completed
Trial end date:
2017-12-14
Target enrollment:
Participant gender:
Summary
This is an open label, multi-center, phase II study of BBI503 administered to adult patients
with advanced hepatobiliary cancer who have exhausted all currently approved standard
anti-cancer treatment options. BBI503 will be administered orally, daily, in continuous
28-day cycles at a dose of 300 mg once daily. Cycles will be repeated until patients are no
longer clinically benefiting from therapy.
Safety, efficacy and tolerability of BBI503 will be assessed for the duration of study
treatment.
Phase:
Phase 2
Details
Lead Sponsor:
Boston Biomedical, Inc Sumitomo Dainippon Pharma Oncology, Inc